Phenazopyridine

Last updated

Phenazopyridine
Phenazopyridine.svg
Clinical data
Trade names Pyridium
AHFS/Drugs.com Monograph
MedlinePlus a682231
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
  • 3-phenyldiazenylpyridine-2,6-diamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.002.149 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C11H11N5
Molar mass 213.244 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Phenazopyridine is a medication which, when excreted by the kidneys into the urine, has a local analgesic effect on the urinary tract. It is often used to help with the pain, irritation, or urgency caused by urinary tract infections, surgery, or injury to the urinary tract.

Contents

In 2021, it was the 285th most commonly prescribed medication in the United States, with more than 700,000 prescriptions. [1] [2]

Medical uses

Phenazopyridine is prescribed for its local analgesic effects on the urinary tract. It is sometimes used in conjunction with an antibiotic or other anti-infective medication at the beginning of treatment to help provide immediate symptomatic relief. Phenazopyridine does not treat infections or injury; it is only used for symptom relief. [3] [4] It is recommended that it be used for no longer than the first two days of antibacterial treatment as longer treatment may mask symptoms. [4]

Phenazopyridine is also prescribed for other cases requiring relief from irritation or discomfort during urination. For example, it is often prescribed after the use of an in-dwelling Foley catheter, endoscopic (cystoscopy) procedures, or after urethral, prostate, or urinary bladder surgery which may result in irritation of the epithelial lining of the urinary tract. [3]

This medication is not used to treat infection and may mask symptoms of inappropriately treated UTI. It provides symptom relief during a UTI, following surgery, or injury to the urinary tract. UTI therapy should be limited to 1–2 days. [4] Long-term use of phenazopyridine can mask symptoms. [5]

Side effects

The characteristic orange-colored urine after taking Phenazopyridine Pyridiumurine.jpg
The characteristic orange-colored urine after taking Phenazopyridine

Phenazopyridine produces a vivid color change in urine, typically to a dark orange to reddish color. This effect is common and harmless, and indeed a key indicator of the presence of the medication in the body. Users of phenazopyridine are warned not to wear contact lenses, as phenazopyridine has been known to permanently discolor contact lenses and fabrics. [3] [6] It also tends to leave an orange-yellow stain on surfaces it comes in contact with. Some may be mistakenly concerned that this indicated blood in the urine.

Phenazopyridine can also cause headaches, upset stomach (especially when not taken with food), or dizziness. Less frequently it can cause a pigment change in the skin or eyes, to a noticeable yellowish color. This is due to a depressed excretion via the kidneys causing a buildup of the medication in the skin, and normally indicates a need to discontinue usage. [4] Other such side effects include fever, confusion, shortness of breath, skin rash, and swelling of the face, fingers, feet, or legs. [3] [4] Long-term use may cause yellowing of nails. [7]

Phenazopyridine should be avoided by people with glucose-6-phosphate dehydrogenase deficiency, [4] [8] [9] [10] because it can cause hemolysis (destruction of red blood cells) due to oxidative stress. [11] It has been reported to cause methemoglobinemia after overdose and even normal doses. [12] In at least one case the patient had pre-existing low levels of methemoglobin reductase, [13] which likely predisposed her to the condition. It has also been reported to cause sulfhemoglobinemia. [4] [14] [15] [16]

Phenazopyridine is an azo dye. [17] [18] Other azo dyes, which were previously used in textiles, printing, and plastic manufacturing, have been implicated as carcinogens that can cause bladder cancer. [19] While phenazopyridine has never been shown to cause cancer in humans, evidence from animal models suggests that it is potentially carcinogenic. [4] [20]

Pregnancy

This medication has shown no adverse events in animal models, but no human trials have been conducted. [4] It is not known if phenazopyridine is excreted in breast milk. [4]

Pharmacokinetics

The full pharmacokinetic properties of phenazopyridine have not been determined. It has mostly been studied in animal models, but they may not be very representative of humans. [21] Rat models have shown its half-life to be 7.35 hours, [22] and 40% is metabolized hepatically (by the liver). [22]

Mechanism of action

Phenazopyridine's mechanism of action is not well known, and only basic information on its interaction with the body is available. It is known that the chemical has a direct topical analgesic effect on the mucosa lining of the urinary tract. It is rapidly excreted by the kidneys directly into the urine. [21] Hydroxylation is the major form of metabolism in humans, [21] and the azo bond is usually not cleaved. [21] On the order of 65% of an oral dose will be secreted directly into the urine chemically unchanged. [4]

Brand names

In addition to its generic form, phenazopyridine is distributed under the following brand names:

Related Research Articles

<span class="mw-page-title-main">Urinary tract infection</span> Infection that affects part of the urinary tract

A urinary tract infection (UTI) is an infection that affects a part of the urinary tract. Lower urinary tract infections may involve the bladder (cystitis) or urethra (urethritis) while upper urinary tract infections affect the kidney (pyelonephritis). Symptoms from a lower urinary tract infection include suprapubic pain, painful urination (dysuria), frequency and urgency of urination despite having an empty bladder. Symptoms of a kidney infection, on the other hand, are more systemic and include fever or flank pain usually in addition to the symptoms of a lower UTI. Rarely, the urine may appear bloody. Symptoms may be vague or non-specific at the extremities of age.

<span class="mw-page-title-main">Benign prostatic hyperplasia</span> Noncancerous increase in size of the prostate gland

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.

<span class="mw-page-title-main">Cystoscopy</span> Medical procedure; endoscopy of the urinary bladder via the urethra

Cystoscopy is endoscopy of the urinary bladder via the urethra. It is carried out with a cystoscope.

<span class="mw-page-title-main">Glucose-6-phosphate dehydrogenase deficiency</span> Medical condition

Glucose-6-phosphate dehydrogenase deficiency (G6PDD), also known as favism, is the most common enzyme deficiency anemia worldwide. It is an inborn error of metabolism that predisposes to red blood cell breakdown. Most of the time, those who are affected have no symptoms. Following a specific trigger, symptoms such as yellowish skin, dark urine, shortness of breath, and feeling tired may develop. Complications can include anemia and newborn jaundice. Some people never have symptoms.

<span class="mw-page-title-main">Paroxysmal nocturnal hemoglobinuria</span> Medical condition

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease of the blood characterized by destruction of red blood cells by the complement system, a part of the body's innate immune system. This destructive process occurs due to deficiency of the red blood cell surface protein DAF, which normally inhibits such immune reactions. Since the complement cascade attacks the red blood cells within the blood vessels of the circulatory system, the red blood cell destruction (hemolysis) is considered an intravascular hemolytic anemia. There is ongoing research into other key features of the disease, such as the high incidence of venous blood clot formation. Research suggests that PNH thrombosis is caused by both the absence of GPI-anchored complement regulatory proteins on PNH platelets and the excessive consumption of nitric oxide (NO).

<span class="mw-page-title-main">Urinalysis</span> Array of tests performed on urine

Urinalysis, a portmanteau of the words urine and analysis, is a panel of medical tests that includes physical (macroscopic) examination of the urine, chemical evaluation using urine test strips, and microscopic examination. Macroscopic examination targets parameters such as color, clarity, odor, and specific gravity; urine test strips measure chemical properties such as pH, glucose concentration, and protein levels; and microscopy is performed to identify elements such as cells, urinary casts, crystals, and organisms.

<span class="mw-page-title-main">Hematuria</span> Presence of blood in urine

Hematuria or haematuria is defined as the presence of blood or red blood cells in the urine. "Gross hematuria" occurs when urine appears red, brown, or tea-colored due to the presence of blood. Hematuria may also be subtle and only detectable with a microscope or laboratory test. Blood that enters and mixes with the urine can come from any location within the urinary system, including the kidney, ureter, urinary bladder, urethra, and in men, the prostate. Common causes of hematuria include urinary tract infection (UTI), kidney stones, viral illness, trauma, bladder cancer, and exercise. These causes are grouped into glomerular and non-glomerular causes, depending on the involvement of the glomerulus of the kidney. But not all red urine is hematuria. Other substances such as certain medications and foods can cause urine to appear red. Menstruation in women may also cause the appearance of hematuria and may result in a positive urine dipstick test for hematuria. A urine dipstick test may also give an incorrect positive result for hematuria if there are other substances in the urine such as myoglobin, a protein excreted into urine during rhabdomyolysis. A positive urine dipstick test should be confirmed with microscopy, where hematuria is defined by three or more red blood cells per high power field. When hematuria is detected, a thorough history and physical examination with appropriate further evaluation can help determine the underlying cause.

<span class="mw-page-title-main">Nitrofurantoin</span> Antibacterial drug

Nitrofurantoin is an antibacterial medication of the nitrofuran class used to treat urinary tract infections, although it is not as effective for kidney infections. It is taken by mouth.

<span class="mw-page-title-main">Sulfasalazine</span> Chemical compound

Sulfasalazine, sold under the brand name Azulfidine among others, is a medication used to treat rheumatoid arthritis, ulcerative colitis, and Crohn's disease. It is considered by some to be a first-line treatment in rheumatoid arthritis. It is taken by mouth or can be administered rectally.

<span class="mw-page-title-main">Hemorrhagic cystitis</span> Medical condition

Hemorrhagic cystitis or haemorrhagic cystitis is an inflammation of the bladder defined by lower urinary tract symptoms that include dysuria, hematuria, and hemorrhage. The disease can occur as a complication of cyclophosphamide, ifosfamide and radiation therapy. In addition to hemorrhagic cystitis, temporary hematuria can also be seen in bladder infection or in children as a result of viral infection.

Glutathione synthetase deficiency (GSD) is a rare autosomal recessive metabolic disorder that prevents the production of glutathione. Glutathione helps prevent damage to cells by neutralizing harmful molecules generated during energy production. Glutathione also plays a role in processing medications and cancer-causing compounds (carcinogens), and building DNA, proteins, and other important cellular components.

<span class="mw-page-title-main">Overactive bladder</span> Condition where a person has a frequent need to urinate

Overactive bladder (OAB) is a common condition where there is a frequent feeling of needing to urinate to a degree that it negatively affects a person's life. The frequent need to urinate may occur during the day, at night, or both. Loss of bladder control may occur with this condition. This condition is also sometimes characterized by a sudden and involuntary contraction of the bladder muscles, in response to excitement or anticipation. This in turn leads to a frequent and urgent need to urinate.

<span class="mw-page-title-main">Cephaloridine</span> Chemical compound

Cephaloridine is a first-generation semisynthetic derivative of antibiotic cephalosporin C. It is a Beta lactam antibiotic, like penicillin. Its chemical structure contains 3 cephems, 4 carboxyl groups and three pyridinium methyl groups.

Urologic diseases or conditions include urinary tract infections, kidney stones, bladder control problems, and prostate problems, among others. Some urologic conditions do not affect a person for that long and some are lifetime conditions. Kidney diseases are normally investigated and treated by nephrologists, while the specialty of urology deals with problems in the other organs. Gynecologists may deal with problems of incontinence in women.

<span class="mw-page-title-main">Pivmecillinam</span> Chemical compound

Pivmecillinam (INN), or amdinocillin pivoxil (USAN), sold under the brand name Selexid and Pivya among others, is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic. Pivmecillinam is the pivaloyloxymethyl ester of mecillinam.

<span class="mw-page-title-main">Drug-induced autoimmune hemolytic anemia</span> Medical condition

Drug-induced autoimmune hemolytic anemia also known as Drug-induced immune hemolytic anemia (DIIHA) is a rare cause of hemolytic anemia. It is difficult to differentiate from other forms of anemia which can lead to delays in diagnosis and treatment. Many different types of antibiotics can cause DIIHA and discontinuing the offending medication is the first line of treatment. DIIHA has is estimated to affect one to two people per million worldwide.

<span class="mw-page-title-main">Sickle cell nephropathy</span> Medical condition

Sickle cell nephropathy is a type of kidney disease associated with sickle cell disease which causes kidney complications as a result of sickling of red blood cells in the small blood vessels. The hypertonic and relatively hypoxic environment of the renal medulla, coupled with the slow blood flow in the vasa recta, favors sickling of red blood cells, with resultant local infarction. Functional tubule defects in patients with sickle cell disease are likely the result of partial ischemic injury to the renal tubules.

<span class="mw-page-title-main">Purple urine bag syndrome</span> Medical condition

Purple urine bag syndrome (PUBS) is a medical syndrome where purple discoloration of urine collection bag occurs in people with urinary catheters and co-existent urinary tract infections. PUBS is most prevalent in elderly females with constipation. Constipation alters the gut bacteria, reducing gastrointestinal motility and leading to increased growth of bacteria in the colon. High bacterial counts in urine are the most important factor causing purple urine bag syndrome. Bacteria in urine produce the enzyme indoxyl sulfatase. This converts indoxyl sulfate in the urine into the red and blue colored compounds indirubin and indigo. People with urinary tract infections using catheters will increase the conversion of indoxyl sulfatase to indirubin and indigo. Indirubin dissolves in plastic and therefore causes urine discoloration. The purple discoloration is the result of reaction between indirubin and plastic urine bags, as well as the presence of indigo. Bacteria in the urine can be found through bacteria culture test. People with purple urine bag syndrome may present with elevated bacterial loads on their culture tests when compared to those who are not affected by this syndrome. The most commonly implicated bacteria are Providencia stuartii, Providencia rettgeri, Klebsiella pneumoniae, Proteus mirabilis, Escherichia coli, Morganella morganii, and Pseudomonas aeruginosa. Purple urine bag syndrome treatment should aim for underlying issues rather than the condition itself. The purple discoloration is harmless and can be resolved with treatments targeted to specific bacteria or any underlying medical conditions. Treatment also consists of providing comfort to both patients and their family, administering antibiotics and performing regular catheter changes. The prognosis is good, however, the morbidity and mortality rates associated with PUBS are elevated depending on patient's underlying health status.

<span class="mw-page-title-main">Abnormal urine color</span> Medical condition

Normally, human urine color is straw-yellow. Urine color other than straw-yellow sometimes reflects an abnormality—an underlying pathological condition—in human beings.

<span class="mw-page-title-main">Antiarthritics</span> Drug class

An antiarthritic is any drug used to relieve or prevent arthritic symptoms, such as joint pain or joint stiffness. Depending on the antiarthritic drug class, it is used for managing pain, reducing inflammation or acting as an immunosuppressant. These drugs are typically given orally, topically or through administration by injection. The choice of antiarthritic medication is often determined by the nature of arthritis, the severity of symptoms as well as other factors, such as the tolerability of side effects.

References

  1. ↑ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  2. ↑ "Phenazopyridine - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  3. 1 2 3 4 "Pyridium Plus Tablets" (PDF). Warner Chilcott. Archived from the original (PDF) on 20 April 2014. Retrieved 15 June 2019.
  4. 1 2 3 4 5 6 7 8 9 10 11 "PYRIDIUM (phenazopyridine) tablet, film coated". DailyMed. Archived from the original on 21 April 2014. Retrieved 15 June 2019.
  5. ↑ Skirrow MB (April 1969). "Urinary tract infections". British Medical Journal. 2 (5648): 687–706. doi:10.1016/j.pop.2013.06.005. PMC   1983013 . PMID   5776230.
  6. ↑ "Phenazopyridine: MedlinePlus Drug Information". Medline plus. American Society of Health-System Pharmacists, Inc. Retrieved 15 June 2019.
  7. ↑ Amit G, Halkin A (December 1997). "Lemon-yellow nails and long-term phenazopyridine use". Annals of Internal Medicine (letter). 127 (12): 1137. doi:10.7326/0003-4819-127-12-199712150-00040. PMID   9412335. S2CID   41928972.
  8. ↑ Tishler M, Abramov A (1983). "Phenazopyridine-induced hemolytic anemia in a patient with G6PD deficiency". Acta Haematologica. 70 (3): 208–209. doi: 10.1159/000206727 . PMID   6410650.
  9. ↑ Galun E, Oren R, Glikson M, Friedlander M, Heyman A (November 1987). "Phenazopyridine-induced hemolytic anemia in G-6-PD deficiency". Drug Intelligence & Clinical Pharmacy. 21 (11): 921–922. doi:10.1177/106002808702101116. PMID   3678069. S2CID   7262697.
  10. ↑ Mercieca JE, Clarke MF, Phillips ME, Curtis JR (September 1982). "Acute hemolytic anaemia due to phenazopyridine hydrochloride in G-6-PD deficient subject". Lancet. 2 (8297): 564. doi:10.1016/s0140-6736(82)90651-1. PMID   6125724. S2CID   27340450.
  11. ↑ Frank JE (October 2005). "Diagnosis and management of G6PD deficiency". American Family Physician. 72 (7): 1277–1282. PMID   16225031. Archived from the original on 28 August 2021. Retrieved 6 July 2009.
  12. ↑ Jeffery WH, Zelicoff AP, Hardy WR (February 1982). "Acquired methemoglobinemia and hemolytic anemia after usual doses of phenazopyridine". Drug Intelligence & Clinical Pharmacy. 16 (2): 157–159. doi:10.1177/106002808201600212. PMID   7075467. S2CID   20968675.
  13. ↑ Daly JS, Hultquist DE, Rucknagel DL (August 1983). "Phenazopyridine induced methaemoglobinaemia associated with decreased activity of erythrocyte cytochrome b5 reductase". Journal of Medical Genetics. 20 (4): 307–309. doi:10.1136/jmg.20.4.307. PMC   1049126 . PMID   6620333.
  14. ↑ Halvorsen SM, Dull WL (September 1991). "Phenazopyridine-induced sulfhemoglobinemia: inadvertent rechallenge". The American Journal of Medicine. 91 (3): 315–317. doi:10.1016/0002-9343(91)90135-K. PMID   1892154.
  15. ↑ Kermani TA, Pislaru SV, Osborn TG (April 2009). "Acrocyanosis from phenazopyridine-induced sulfhemoglobinemia mistaken for Raynaud phenomenon". Journal of Clinical Rheumatology. 15 (3): 127–129. doi:10.1097/RHU.0b013e31819db6db. PMID   19300288.
  16. ↑ Gopalachar AS, Bowie VL, Bharadwaj P (June 2005). "Phenazopyridine-induced sulfhemoglobinemia". The Annals of Pharmacotherapy. 39 (6): 1128–1130. doi:10.1345/aph.1E557. PMID   15886294. S2CID   22812461.
  17. ↑ Cystitis in Females~treatment at eMedicine
  18. ↑ "Phenazopyridine Hydrochloride". The American Society of Health-System Pharmacists. Retrieved 30 June 2015.
  19. ↑ Transitional Cell Carcinoma Imaging at eMedicine
  20. ↑ "Phenazopyridine Hydrochloride" (PDF). Report on Carcinogens, Twelfth Edition (2011). National Toxicology Program. Archived from the original (PDF) on 17 February 2013. Retrieved 15 June 2019.
  21. 1 2 3 4 Thomas BH, Whitehouse LW, Solomonraj G, Paul CJ (April 1990). "Excretion of phenazopyridine and its metabolites in the urine of humans, rats, mice, and guinea pigs". Journal of Pharmaceutical Sciences. 79 (4): 321–325. doi:10.1002/jps.2600790410. PMID   2352143.
  22. 1 2 Jurima-Romet M, Thomas BH, Solomonraj G, Paul CJ, Huang H (March 1993). "Metabolism of phenazopyridine by isolated rat hepatocytes". Biopharmaceutics & Drug Disposition. 14 (2): 171–179. doi:10.1002/bdd.2510140208. PMID   8453026. S2CID   29419875.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.